Elizabeth Plimack, MD
Enriched profileDeputy Director and Professor, Department of Hematology/Oncology; Chief, Division of Genitourinary Medical Oncology, Fox Chase Cancer Center · Fox Chase Cancer Center
Elizabeth Plimack is Deputy Director and Professor, Department of Hematology/Oncology; Chief, Division of Genitourinary Medical Oncology, Fox Chase Cancer Center at Fox Chase Cancer Center. OpenAlex indexes 776 publications with 49,784 citations (h-index 80); ClinicalTrials.gov lists 4 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 17 Aug 2026
Overview
Updated 14 Oct 2026
Elizabeth Plimack, M.D., is Deputy Director and Professor, Department of Hematology/Oncology at Fox Chase Cancer Center. The public record shows 776 publications with 49,784 citations (h-index 80), centered on Bladder and Urothelial Cancer Treatments, Cancer Immunotherapy and Biomarkers, Renal cell carcinoma treatment. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 27 companies.
- Most recent indexed publication: 2026 · JCO oncology practice
- Top research focus: Bladder and Urothelial Cancer Treatments
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 27 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 21 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 258.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer
Sponsor: Fox Chase Cancer Center
- Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma
Sponsor: Fox Chase Cancer Center
Industry payments
Updated 14 Oct 2026
27 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202515 payments$18,352openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year20254 payments
- UROGEN PHARMA, INC.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
66.3%Cytochrome P450 17A1 Inhibitor32.6%Abiraterone Acetate100%Part D≥25 patientsKinase inhibitor14.7%Votrient45%Inlyta27%Lenvima27%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
29%Corticosteroid25.7%Prednisone100%Part D≥28 patientsSerotonin-3 Receptor Antagonist3.3%Ondansetron Hcl100%Part D≥18 patientsNervous system
2.4%Opioid Agonist2.4%Oxycodone Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Oct 2026
199 congress contributions (2008–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Assessing impact of RDI on outcomes in patients treated with enfortumab vedotin-pembrolizumab combination therapy.
ASCO Annual Meeting
ASCO2026Co-author - Assessing the impact of cardiovascular disease and ADT on survival disparities in prostate cancer.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Gender Disparities in Citations and Altmetric Attention Score in Oncology.
JCO oncology practice
Article2026 - End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer.
Journal of clinical oncology
Article2025 - Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).
Journal of clinical oncology
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaArticle5,931 citations2015
- 02Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaArticle4,702 citations2018
- 03Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaArticle3,448 citations2019
- 04Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapyArticle2,374 citations2018
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/elizabeth-plimack-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/elizabeth-plimack-10492899
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
profiles.foxchase.org/en/persons/elizabeth-r-plimack
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.foxchase.org ↗ - Other
ncbi.nlm.nih.gov/myncbi/elizabeth.plimack.1/bibliography/public
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ncbi.nlm.nih.gov ↗ - X / Twitter
x.com/erplimackmd
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/fox-chase-cancer-center_dr-elizabeth-plimack-appointed-deputy-director-activity-6917565602316320768-j7im
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
bcan.org/the-bladder-cancer-room-where-it-happens-with-dr-elizabeth-plimack
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcan.org ↗ - Other
connection.asco.org/do/meet-elizabeth-r-plimack-md-ms
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →connection.asco.org ↗ - Other
en.wikipedia.org/wiki/Elizabeth_Plimack
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foxchase.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foxchase.org ↗
- Board Certified
Medical Oncology, American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foxchase.org ↗ - Internal Medicine residency
NYU Medical Center/Bellevue Hospital; Medical Oncology fellowship, MD Anderson Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.foxchase.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foxchase.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foxchase.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foxchase.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foxchase.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foxchase.org ↗
- Panel Member
NCCN Guidelines Panels for Bladder/Penile, Kidney/Testicular, and Prostate Cancers
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foxchase.org ↗ - Member
Bladder Cancer Advocacy Network Management and Think Tank Steering Committees
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcan.org ↗ - Member
American Joint Committee on Cancer (AJCC) Urinary Tract Expert Panel
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bcan.org ↗ - Advisor
Society of Urologic Oncology Clinical Trials Consortium
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foxchase.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foxchase.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.foxchase.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foxchase.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foxchase.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foxchase.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foxchase.org ↗
Secondary affiliations
appointments beyond the home institution- Affiliated faculty
Cancer Epigenetics Institute and Nuclear Dynamics and Cancer (NDC) program, Fox Chase Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.foxchase.org ↗
Media & interviews
press, podcasts and appearances- Podcast guest
"The Bladder Cancer Room Where It Happens" (host Rick Bangs), Bladder Cancer Advocacy Network
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcan.org ↗ - Video interview
"Dr. Elizabeth Plimack on Ipilimumab and PD-L1 Inhibitors in the Treatment of Bladder Cancer," Targeted Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →targetedonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Martin Edelman, MD
Fox Chase Cancer Center
Shazia Nakhoda, MD
Fox Chase Cancer Center
Robert Uzzo, MD02041967
Fox Chase Cancer Center
Margaret Von-Mehren, MD
Fox Chase Cancer Center
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)